Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

By A. Lincoff, K. Wolski, S. Nicholls, S. Nissen. Journal of the American Medical Association (JAMA), 2007

1,264 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/854b5b85f0477599f1c736ab69e8886fd1a3b88b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Molecular Biology

Citations in the corpus

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. (2008, result): “In addition, rosiglitazone has been associated with an increased risk of myocardial infarction or other ischemic events in several meta-analyses, whereas a similar metaanalysis of pioglitazone showed a reduction in the risk of adverse cardiovascular outcomes.(30,31) Furthermore, a well-controlled ra”
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013, background): “Conversely, the evidence for pioglitazone suggests a possible reduced risk of cardiovascular events, although heart failure and increased fractures are still concerning side effects (35,36).”
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009, background): “Meta-analyses have supported a possible beneficial effect of pioglitazone on CVD risk (68).”
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications (2020, neutral): “120 Another meta-analysis investigating the effect of pioglitazone on risk of CVD events showed a benefit with pioglitazone in both patients with pre-diabetes (or insulin resistance) and those with T2DM.”
Atherosclerosis: current pathogenesis and therapeutic options (2011, background): “Likewise, pioglitazone, despite lowering cardiovascular risk in patients with diabetes, has been linked to serious heart failur”
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008, positive): “Meta-analyses have supported a possible beneficial effect of pioglitazone on CVD risk [68].”
Type 2 diabetes in children and adolescents (2003, neutral): “The family should be encouraged to make dietary changes consistent with healthy eating recommendations, including individualized counseling for weight reduction, reduced total and saturated fat intake, increased fiber intake, and increased physical activity (80).”
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. (2013, background): “Moreover, these compounds are associated with a significant increase in weight and concerns have been raised about the cardiovascular safety of rosiglitazone, although pioglitazone has been shown to improve all-cause mortality, including cardiovascular outcomes.(8) In addition, long-term ( 5 years) ”